Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25042 intravitreal injection solution receives clinical trial approval
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SQ-25042 intravitreal injection solution. SQ-25042 intravitreal injection solution is a fusion protein independently developed by the company and is a Class 1 innovative therapeutic biologic product. It is intended clinically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO).
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SQ-25042 intravitreal injection solution. SQ-25042 intravitreal injection solution is a fusion protein independently developed by the company and is a Class 1 innovative therapeutic biologic product. It is intended for clinical use in the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO).
Related Articles

Jinan Shengquan Group Share Holding (605589.SH) Chairman proposes share buyback of RMB200 million to RMB400 million.

Xtc New Energy Materials (Xiamen) Co., Ltd. (688778.SH) Chairman proposes share repurchase of RMB50 million to RMB100 million.

SDIC Intelligence Information Technology (300188.SZ) plans to increase capital by RMB200 million in its subsidiary.
Jinan Shengquan Group Share Holding (605589.SH) Chairman proposes share buyback of RMB200 million to RMB400 million.

Xtc New Energy Materials (Xiamen) Co., Ltd. (688778.SH) Chairman proposes share repurchase of RMB50 million to RMB100 million.

SDIC Intelligence Information Technology (300188.SZ) plans to increase capital by RMB200 million in its subsidiary.






